WuXi Biologics (300357.SZ): Terminates research and development project for nicotine production using yeast.

Zh tng cijng APP xn, W w shngw (300357.SZ) fb gnggo, rqin, gngs gunl cng du yn q mi din c y ynf xingm jnxngle shnzhn pngg, zngh xingm jnzhn qngkung, jx kif de fngxin dng duzhng yns, wi hl pizh gngs ynf zyun, jzh ynf gunxin zhng de yush xingm, gngs judng zhngzh yn q mi din c y ynf xingm, b zi kizhn hux de lnchng shyn. Information from Zhtng Financial APP, Wuhan Biological (300357.SZ) issued an announcement. Recently, the company's management carefully evaluated the research and development project of tobacco mildew prick injection, considering various factors such as project progress, risks of continued development, etc. In order to reasonably allocate the company's research and development resources and focus on advantageous projects in the research and development pipeline, the company has decided to terminate the research and development project of tobacco mildew prick injection and will no longer conduct further clinical trials.